Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)

被引：0

作者：

Kuzuya, T. ^{[1
]}

Yamashita, T. ^{[2
]}

Takehara, T. ^{[3
]}

Aikata, H. ^{[4
]}

Kato, N. ^{[5
]}

Hiasa, Y. ^{[6
]}

Nakamura, S. ^{[7
]}

Morimoto, N. ^{[8
]}

Moriguchi, M. ^{[9
]}

Ikeda, M. ^{[10
]}

Inoue, J. ^{[11
]}

Tani, J. ^{[12
]}

Ueno, Y. ^{[13
]}

Chayama, K. ^{[14
]}

Tateishi, R. ^{[15
]}

Kawamura, Y. ^{[16
]}

Furuse, J. ^{[17
]}

Kudo, M. ^{[18
]}

Yamamoto, K. ^{[19
]}

Kokudo, N. ^{[20
]}

机构：

[1] Fujita Hlth Univ, Dept Gastroenterol & Hepatol, Toyoake, Aichi, Japan

[2] Kanazawa Univ, Gastroenterol Dept, Kanazawa, Ishikawa, Japan

[3] Osaka Univ, Gastroenterol & Hepatol, Suita, Osaka, Japan

[4] Hiroshima Prefectural Hosp, Gastroenterol, Minami, Japan

[5] Chiba Univ, Sch Med, Gastroenterol, Chiba, Japan

[6] Ehime Univ, Grad Sch Med, Gastroenterol & Metabol, Toon, Japan

[7] Japanese Red Cross Soc, Himeji Hosp, Internal Med, Himeji, Hyogo, Japan

[8] Jichi Med Univ Hosp, Dept Med, Div Gastroenterol, Shimotsuke, Tochigi, Japan

[9] Kyoto Prefectural Univ Med, Mol Gastroenterol & Hepatol, Kyoto, Japan

[10] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Kashiwa, Chiba, Japan

[11] Tohoku Univ Hosp, Dept Gastroenterol, Sendai, Miyagi, Japan

[12] Kagawa Univ, Fac Med, Grad Sch Med, Dept Gastroenterol & Neurol, Miki, Kagawa, Japan

[13] Yamagata Univ, Gastroenterol, Fac Med, Yamagata, Japan

[14] Hiroshima Univ Hosp, Collaborat Res Lab Med Innovat, Hiroshima, Japan

[15] Univ Tokyo Hosp, Dept Gastroenterol, Bunkyo ku, Tokyo, Japan

[16] Toranomon Gen Hosp, Hepatol, Minato, Japan

[17] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Kanagawa, Japan

[18] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[19] Yokohama City Univ Med, Dept Biostat, Yokohama, Kanagawa, Japan

[20] NCGM Natl Ctr Global Hlth & Med, Surg, Shinjuku Ku, Tokyo, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.283

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

148P

引用

页码：S1531 / S1532

页数：2

共 50 条

[31] Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis
Changez, Mah I. Kan
Khan, Maimoona
Uzair, Muhammad
Tahir, Muhammad Fawad
Mohsin, Maryam
Hussain, Amna Faiyaz
Saqib, Vania
Molani, Muhammad Khizer
Ahmed, Aisha Habib
Khalid, Saad
JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (01) : 467 - 481
[32] The safety of atezolizumab plus bevacizumab (atezo/bev) treatment in Chinese patients (pts) with hepatocellular carcinoma (HCC) with active hepatitis B virus (HBV) infection: Results from the TALENTop study.
Zhu, Xiao-Dong
Sun, Hui-Chuan
Shen, Feng
Bai, Xueli
Chen, Minshan
Huang, Zhiyong
Song, Tianqiang
Zeng, Yongyi
Kuang, Ming
Xiang, Bangde
Liu, Lianxin
Li, Deyu
Wen, Tianfu
Chen, Yongjun
Peng, Tao
Li, Xiangcheng
Zhou, Jian
Fan, Jia
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[33] THE EFFICACY AND SAFETY OF ATEZOLIZUMAB & BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: THE REAL WORLD DATA
Yoo, Sung Hwan
Lee, Hyun Woong
Lee, Jung Il
HEPATOLOGY, 2023, 78 : S1898 - S1899
[34] IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) 1 bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
Cheng, A-L.
Qin, S.
Ikeda, M.
Galle, P.
Ducreux, M.
Zhu, A.
Kim, T-Y.
Kudo, M.
Breder, V.
Merle, P.
Kaseb, A.
Li, D.
Verret, W.
Xu, Z.
Hernandez, S.
Liu, J.
Huang, C.
Mulla, S.
Lim, H. Y.
Finn, R.
ANNALS OF ONCOLOGY, 2019, 30
[35] Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
Cheon, Jaekyung
Yoo, Changhoon
Hong, Jung Yong
Kim, Han Sang
Lee, Dae-Won
Lee, Myung Ah
Kim, Jin Won
Kim, Ilhwan
Oh, Sang-Bo
Hwang, Jun-Eul
Chon, Hong Jae
Lim, Ho Yeong
LIVER INTERNATIONAL, 2022, 42 (03) : 674 - 681
[36] Effectiveness and safety of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: A multicenter, retrospective real-world study in China
Zhang, Hui
Shao, Minghua
Tan, Binbin
Fu, Yin
Yuan
Chen, Hailei
CANCER RESEARCH, 2024, 84 (06)
[37] A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo plus bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh class B cirrhosis: CHALLENGE trial final results.
Ikeda, Masafumi
Terashima, Takeshi
Yamashita, Tatsuya
Okusaka, Takuji
Imaoka, Hiroshi
Kawaoka, Tomokazu
Kobayashi, Satoshi
Ogasawara, Sadahisa
Hiraoka, Atsushi
Nakano, Masahito
Nagashima, Fumio
Sugimoto, Rie
Moriguchi, Michihisa
Inaba, Yoshitaka
Shinoda, Satoru
Ueno, Makoto
Kato, Naoya
Kudo, Masatoshi
Furuse, Junji
Nagano, Hiroaki
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[38] Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series
Sakaguchi, Koki
Satoh, Tatsunori
Kawaguchi, Shinya
Aoyama, Takuya
Asahara, Kazuhisa
Endo, Shinya
Shirane, Naofumi
Kanemoto, Hideyuki
Oba, Noriyuki
Ohno, Kazuya
CLINICAL JOURNAL OF GASTROENTEROLOGY, 2024, 17 (03) : 515 - 522
[39] Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Junning Liu
Linfeng Yang
Song Wei
Jijiang Li
Pengsheng Yi
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 16191 - 16201
[40] Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Liu, Junning
Yang, Linfeng
Wei, Song
Li, Jijiang
Yi, Pengsheng
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (17) : 16191 - 16201

← 1 2 3 4 5 →